Prospective CT Confirms Differnces Between Vascular and Alzheimer's Dementia
Stroke 26:735-742, Meyer,J.S.,et al, 1995
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Utility of Clinical Criteria in Differentiating Frontotemporal Lobar Degeneration (FTLD) From AD
Neurol 58:1608-1615, Rosen,H.J.,et al, 2002
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
A Clinical Role for 99mTC-HMPAO SPECT in the Investigation of Dementia
JNNP 64:306-313, Talbot,P.R.,et al, 1998
Preclinical Prediction of Alzheimer's Disease Using SPECT
Neurol 50:1563-1571, Johnson,K.A.,et al, 1998
Longitudinal Study of CSF Levels of Tau, A beta 1-40, and A beta 1-42 (43) in Alzheimer's Disease
Ann Neurol 44:17-26, 61998., Kanai,M.,et al, 1998
New Neuropathological Criteria for Alzheimer Disease
Arch Neurol 55:1174-1176, Hyman,B.T., 1998
Assessment of CSF Levels of Tau Protein in Mildly Demented Patients with Alzheimer's Disese
Neurol 48:632-635, Galasko,D.,et al, 1997
Frontotemporal Dementia and Early Alzheimer Disease:Differentiation with Frontal Lobe H-1 MR Spectroscopy
Radiology 203:829-836, Ernst,T.,et al, 1997
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the e4Allele for Apolipoprotein E
NEJM 334:752-758, 7911996., Reiman,E.M.,et al, 1996
Diagnostic Value of SPECT with Tc 99m HMPAO in Alzheimer's Disease:A Population-Based Study
Neurol 44:454-461, Claus,J.J.,et al, 1994
Differential Diagnosis in Dementia, Principal Components Analysis of Clinical Data From a Population Survey
Arch Neurol 50:72-77, Jorm,A.F.,et al, 1993
Blinded Clinical Evaluation of Positron Emission Tomography for Diagnosis of Probable Alzheimer's Disease
Neurol 42:765-770, Powers,W.J.,et al, 1992
Detection in Life of Confirmed Alzheimer's Disease, Medial Temporal Lobe Atrophy by Computed Tomography
Lancet 340:1179-1183, Jobst,K.A.,et al, 1992
Anomalous Molecular Form of Acetylcholinesterase in CSF in Histologically Diagnosed Alzheimer's Disease
Lancet 337:447-450, Navaratnam,D.S.,et al, 1991
Single-Photon Emission Computed Tomography (SPECT)
JAMA 263:561-564, Holman,B.L.&Tumeh,S.S., 1990
Iofetamine I 123 Single Photon Emission Computed Tomography is Accurate in Diagnosis of Alzheimer's Disease
Arch Int Med 150:752-756, Johnson,K.A.,et al, 1990
Brain Amyloid and Alzheimer Disease
Ann Int Med 109:41-54, Vinters,H.V.,et al, 1988
Positron Emission Tomography in Alzheimer's Disease
Neurol 36:879-887, Duara,R.,et al, 1986
Cerebrospinal Fluid Acetylcholinesterase Activity in Senile Dementia of the Alzheimer Type
Ann Neurol 17:46-48, Tune,L.,et al, 1985